Top news
-
-
The evolution of this growing demand and how at Angelini Pharma we can support it
-
-
Changes in the CDMO/CLIENT relationship model post the CoVid era
-
Sustainability: exploring its significance at Angelini Pharma
-
-
CDMO - CRDMO: tools and different business model for new opportunity in synthesis
-
Impact of Covid-19 on global pharmaceutical production and trade
-
-
“CRDMO” the new business model for future of the (Bio)Pharma Industry
-
-
-
Flow Chemistry as novel chirotechnologic tool for asymmetric synthesis of APIs
-
Angelini Fine Chemicals increases the production of High Potent Active Pharmaceutical Ingredients
-
Modern and future strategic trends of the pharma outsourcing market
News & publications
-
PHARMA 4.0: Race to digitalization
Digitalization in the pharmaceutical industry refers to the integration and adoption of digital technologies to fundamentally change how companies operate, deliver value, and interact with stakeholders. It goes beyond individual technology implementations and is related to a re-design of business processes, organizational culture, and customer experiences.
-
Sustainability: exploring its significance at Angelini Pharma
Sustainability has been a frequently mentioned concept over the last few years across many manufacturing platforms but more recently has become a popular topic within the pharmaceutical industry.
-
DCAT Week 2025
DCAT Week is the perfect networking event for companies engaged in pharmaceutical development and manufacturing and related industries...
-
15th Annual World ADC London 2025
World ADC London is the leading European conference uniting over 1000 ADC enthusiasts to maximise the therapeutic index of ADCs, focused on advancing the development and commercialization of antibody-drug conjugates...
-
BIO-EUROPE SPRING
BIO-Europe Spring connects Europe’s top innovation centers with the global life sciences industry to cultivate thriving strategic partnerships...
-
Green API manufacturing
As generic competition increases it is crucial to examine different ways to improve efficiency and cost reduction in the manufacturing process for the active pharmaceutical ingredient (API).
-
CPhI Japan
International business platform in the pharmaceutical sector. CPhI Japan is Japan's most comprehensive pharma event, which brings together more than 26,000 pharma industry professionals from 60 countries.
-
CDMO - CRDMO: tools and different business model for new opportunity in synthesis
The active pharmaceutical ingredient (API) is the foundation of a final drug product and is a crucial consideration when choosing a Contract Development and Manufacturing Organisation (CDMO) or Contract Research (in House) Development and Manufacturing Organisation (CRDMO).
-
Impact of Covid-19 on global pharmaceutical production and trade
Drugs & APIs shortage is a global issue with an evident impact affecting all the people independently of their geographic or economic position.
-
An overview of the US pharma landscape
Over the past 10+ years the pharmaceutical Industry has utilized CDMO’s at an increasing level from year to year never seen prior to this period...
-
“CRDMO” the new business model for future of the (Bio)Pharma Industry
Today CDMOs face excellent growth opportunities in a pharmaceutical market environment where using outsourcing services is becoming the new norm...
-
Angelini Pharma continues its commitment to HPAPI services
Facing the rising number of custom HPAPIs demand, Angelini Fine Chemicals decided to expand its HPAPI capacity at its Aprilia,Italy plant site
-
Flow Chemistry as novel chirotechnologic tool for asymmetric synthesis of APIs
The continuous-flow enantioselective processes have to be seen as a pivot point for sustainable development of the tomorrow’s pharmaceutical industry
-
Modern and future strategic trends of the pharma outsourcing market
Today Contract Development Manufacturing Organizations (CDMOs) face excellent growth opportunities in a pharmaceutical market environment where using outsourcing services is becoming the new norm
Who we are
-
What we do
Since 1967, branded and generic pharmaceutical industries have been relying on Angelini Fine Chemicals to accelerate their R&D portfolio to the pharmaceutical market.
-
Our Business Model
Since its foundation, chemistry, technology and people set the ground for Angelini Fine Chemicals. Angelini culture remains true to these values and define how we conduct our business today.
-
Our plant
With over 50 years of experience in pharmaceuticals manufacturing industry, Angelini Fine Chemicals is one of the major API manufacturers in Italy and Europe.
Our services
-
Custom synthesis
Angelini Fine Chemicals helps pharmaceutical customers bringing new brand drugs to market.
-
Project management
Angelini Fine Chemicals offers a dedicated project team to coordinate every aspect of chemical development for your small molecules.
-
Supply chain management
Angelini Fine Chemicals recognizes the importance of Supply Chain Management and its role to support Company and Customer competitiveness.
-
Regulatory support
As a CDMO involved in the manufacture of RSMs and APIs, Angelini Fine Chemicals constantly reviews regulatory developments in all relevant pharmaceutical markets.
R&D
-
API expertise
Angelini’s strength in API Research & Development is proven by being the partner of choice for large pharma and smaller biotech companies seeking integrated drug development solutions to accelerate R&D pipelines from bench to market.
-
Kilo-lab
Angelini R&D team can rapidly develop scalable, robust and cost-effective chemical synthesis that can be readily transferred to our kilo-labs either as a proof of concept study, or for scale-up and delivery of material to support your early clinical supply as well as small volume API and HPAPI.
-
Reaction Technology
Angelini Fine Chemicals has a long tradition in API industry and has built up a comprehensive capability and expertise to carry out complex and hazardous operations for the manufacturing API and HPAPI, safely, in accordance with cGMP standards and customer quality expectations.
-
Analytical development equipment
The API chemical development is backed-up by comprehensive analytical development capabilities utilizing state-of-the-art R&D labs.